Daewon Pharm (003220) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of Daewon Pharm stock KRW 1,145, price KRW 8,000, upside -85.7%, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range 7,300 KRW – 21,237 KRW · fair‑value band 1,145 KRW – 2,699 KRW · the 8,000 KRW price screens above the 1,145 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Daewon Pharm in your weekly email
Every Wednesday you see whether Daewon Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use.
Show moreShow less
The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease.
It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Stock analysis
Daewon Pharm (003220) currently trades at 8,000 KRW, while our model-based Fair Value estimate is 1,145 KRW, 85.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 10,761 KRW per share, and 3 of the 10 models we run sit above the 8,000 KRW price.
Bear case: the Growth DCF group reads lowest at 988.19 KRW, and 7 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1,145 KRW (bear) to 2,699 KRW (bull), the price of 8,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Daewon Pharm reported revenue of 605B KRW in FY2025 versus 354B KRW in FY2021, a compound +14.3%/yr. Reported net income was −1.4B KRW in FY2025.
Key figures
Market cap 171B KRW (≈ $129M) Micro · P/S ratio 0.27 · Dividend yield 3.1% · Net margin 0.4% · Return on equity 0.8% · Return on assets (EBIT) 5.2% · Operating margin 0.0% · Revenue (TTM) 615B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −86%, 003220 screens richer than that median.
Fair Value models
Bear1,145 KRWFair Value 1,145 KRWBull2,699 KRW
Price 8,000 KRW · Upside -85.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Start year 2020 (pandemic). Over 10 years: +10.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.8% (2020) → 0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +3.5% a year for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 576 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside−85.7% · Bottom 25%
Profitability
Return on equity (12 months)0.8% · Below median
Return on assets−0.2% · Below median
Net margin (12 months)0.4% · Below median
Operating margin (12 months)0.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)6.2% · Above median
Dividend yield (12 months)3.1% · Above median
Balance sheet
Debt / equity0.31× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.64× · Cheapest 25%
P/S (12 months)0.28× · Cheapest 25%
EV/EBITDA8.5× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)31· sector 26
PAST (return on equity)3· sector 28
HEALTH (low debt)84· sector 96
DIVIDEND (yield)63· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Daewon Pharm Fair Value". https://www.fairvalue-calculator.com/stock/003220
Frequently asked questions
Is Daewon Pharm (003220) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 1,145 KRW versus a price of 8,000 KRW, about −86% upside (overvalued).
What is the fair value of 003220?
Our model-based fair value for Daewon Pharm is 1,145 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 8,000 KRW.
What is the quality score of 003220?
Daewon Pharm has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daewon Pharm (003220)?
Our model-based price target is the fair value of 1,145 KRW (as of Oct 2, 2026) from 10 valuation models. Cautious scenario 1,145 KRW, optimistic scenario 2,699 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daewon Pharm stock forecast for 2026?
Our models put fair value at 1,145 KRW, about −86% upside versus a price of 8,000 KRW (overvalued). Cautious scenario 1,145 KRW, optimistic scenario 2,699 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daewon Pharm (003220)?
Daewon Pharm reported trailing-twelve-month revenue of about 615B KRW (latest available figure, as of Oct 2, 2026).
Does Daewon Pharm pay a dividend?
Daewon Pharm currently shows a dividend yield of 3.13% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Daewon Pharm (003220)?
For today's price to be fair in a discounted-cash-flow model, Daewon Pharm would have to grow free cash flow by more than 80 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.4 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 003220 use?
Our models discount Daewon Pharm at 11.6 %: a base by market capitalisation (micro), damped by beta 0.15, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daewon Pharm that is more than 80 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Daewon Pharm (003220) delivered so far?
Over the past 5 years revenue at Daewon Pharm grew +14.4 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daewon Pharm (003220) growing?
The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into Daewon Pharm (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daewon Pharm (003220)?
The free-cash-flow yield on the price is 0.11 %: that much free cash flow Daewon Pharm produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daewon Pharm (003220)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daewon Pharm it is 1,145 KRW per share (as of Oct 2, 2026), against a price of 8,000 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Daewon Pharm stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 003220 trades above its calculated fair value: price 8,000 KRW, fair value 1,145 KRW, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003220?
No. The price is what the market pays today (8,000 KRW); the fair value is what the company's own numbers justify (1,145 KRW). For Daewon Pharm the two are 6,855 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daewon Pharm worth?
The market values Daewon Pharm at about 171B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 8,000 KRW; our models calculate a fair value of 1,145 KRW per share.
What do the bullish and bearish scenarios say about 003220?
Our models span a range for Daewon Pharm: cautious scenario 1,145 KRW, base 1,145 KRW, optimistic 2,699 KRW per share (as of Oct 2, 2026, price 8,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daewon Pharm (003220)?
Balance-sheet figures for Daewon Pharm (as of Oct 2, 2026): return on equity 0.8%, debt of 0.31 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 003220 from its 52-week high?
Daewon Pharm trades at 8,000 KRW, about 39% below its 52-week high of 13,174 KRW and 10% above the low of 7,300 KRW (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of 1,145 KRW is for.
Which stocks are comparable to Daewon Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daewon Pharm stock attractive at the current price?
The data as of Oct 2, 2026: price 8,000 KRW, calculated fair value 1,145 KRW (−86%), Quality Score 42/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003220 calculated?
We run Daewon Pharm through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,145 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Daewon Pharm itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daewon Pharm (003220)?
The closing price on Oct 19, 2026 was 8,000 KRW. Our model-based fair value is 1,145 KRW, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daewon Pharm right now?
The price sits above even our optimistic bull case (2,699 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,145 KRW to 2,699 KRW) leaves room in how you read the outcome.
Key figures of Daewon Pharm
How large is the market capitalisation of Daewon Pharm (003220)?
The market capitalisation of Daewon Pharm is 171B KRW (≈ $129M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daewon Pharm (003220)?
The price-to-sales ratio of Daewon Pharm is 0.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Daewon Pharm (003220)?
The dividend yield of Daewon Pharm is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daewon Pharm (003220)?
The net margin of Daewon Pharm is 0.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daewon Pharm (003220)?
The return on equity (ROE) of Daewon Pharm is 0.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daewon Pharm (003220)?
On an EBIT basis the return on assets of Daewon Pharm is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daewon Pharm (003220)?
The operating margin of Daewon Pharm is 0.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daewon Pharm (003220)?
Revenue at Daewon Pharm is growing +6.2% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daewon Pharm (003220)?
Earnings per share at Daewon Pharm are growing −56.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Daewon Pharm (003220) carry?
The net debt of Daewon Pharm is 151B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Daewon Pharm in the live analysis
One click puts Daewon Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 2, 2026